The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
 
Jeff P. Sharman
Consulting or Advisory Role - Abbvie; Acerta Pharma; Celgene; Pharmacyclics; TG Therapeutics
Research Funding - Acerta Pharma; Celgene; Pharmacyclics; TG Therapeutics
 
Danielle M. Brander
Honoraria - Abbvie; Genentech; Teva; TG Therapeutics
Consulting or Advisory Role - Abbvie; Genentech; Novartis; Pharmacyclics; Teva; TG Therapeutics
Travel, Accommodations, Expenses - Abbvie; Teva; TG Therapeutics
Other Relationship - Novartis
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; Celgene; Janssen Oncology; Loxo; PER; Pharmacyclics; Prime Oncology; Sunesis Pharmaceuticals; TG Therapeutics; Verastem; Verastem
Research Funding - Abbvie/Genentech; Adaptive Biotechnologies; BeiGene; Genentech; LOXO; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics; Verastem
Travel, Accommodations, Expenses - Pfizer; TG Therapeutics
Other Relationship - Celgene; TG Therapeutics
 
Nilanjan Ghosh
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen Oncology; Kite/Gilead; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
Stephen J. Schuster
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Alimera Sciences; BeiGene; Celgene; Juno Therapeutics; Loxo; Nordic Nanovector; Novartis; Tessa Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Suman Kambhampati
No Relationships to Disclose
 
John M. Burke
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Celgene; Genentech/Roche; Juno Therapeutics; Kite/Gilead; Seagen; Tempus
Speakers' Bureau - Seagen
Research Funding - Janssen
 
Frederick Lansigan
Consulting or Advisory Role - Celgene; Seagen; Spectrum Pharmaceuticals
Research Funding - Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Marshall T. Schreeder
Research Funding - TG Therapeutics (Inst)
 
Scott D Lunin
No Relationships to Disclose
 
Alexander Zweibach
Research Funding - TG Therapeutics (Inst)
 
Mikhail Shtivelband
No Relationships to Disclose
 
Patrick M. Travis
Research Funding - TG Therapeutics (Inst)
 
Jason Claud Chandler
Research Funding - TG Therapeutics (Inst)
 
Kathryn S. Kolibaba
Employment - Compass Oncology
Consulting or Advisory Role - Atara Biotherapeutics; TG Therapeutics; Tolero Pharmaceuticals
Research Funding - Acerta Pharma; Celgene; CTI; Genentech; Gilead Sciences; Novartis; Pharmacyclics; Seagen; TG Therapeutics
Travel, Accommodations, Expenses - Tolero Pharmaceuticals
 
Peter Sportelli
Employment - TG Therapeutics
Stock and Other Ownership Interests - TG Therapeutics
Travel, Accommodations, Expenses - TG Therapeutics
 
Hari P. Miskin
Employment - TG Therapeutics
Stock and Other Ownership Interests - TG Therapeutics
Travel, Accommodations, Expenses - TG Therapeutics
 
Michael S. Weiss
Employment - TG Therapeutics
Leadership - TG Therapeutics
Stock and Other Ownership Interests - Fortress Biotech; TG Therapeutics
Travel, Accommodations, Expenses - TG Therapeutics
 
Ian Flinn
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Gilead Sciences (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Nurix (Inst); Roche (Inst); Seagen (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Curis (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Juno Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Merck (Inst); MorphoSys (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)